Monopar Therapeutics(MNPR) - 2025 Q4 - Annual Results

Exhibit 99.1 Monopar Reports Fourth Quarter and Full-Year 2025 Financial Results and Provides Business Update Wilmette, Ill., March 27, 2026 – Monopar Therapeutics Inc. ("Monopar," the "Company," "we") (Nasdaq: MNPR), a clinical-stage biopharmaceutical company developing innovative treatments for patients with unmet medical needs, today announced the fourth quarter and full-year 2025 financial results and provided a summary of recent developments. "2025 was a productive year for Monopar, marked by multiple ...